CryptoMedix

CryptoMedix Inc (CMx) is an early stage biotechnology company, dedicated to the development of novel targeted immuno-therapeutics for cancer.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Portland, Maine, US
  • Currency USD
  • Founded June 2013
  • Employees 0
  • Incorporation Type C-corp

Company Summary

CryptoMedix is developing first-in-class novel immuno-therapeutics for cancer. CMx antibodies block the activities of “cryptic” fragments of collagen. Studies in animal models have shown CMx antibodies to inhibit tumorigenesis and re-activate the immune response. CMx plans to complete testing and initiate early stage clinical trials with its lead compound by 2019. Our goal is to be in Phase 2 trials, seeking an exit, by 2021.

Team

  • Janet Yancey-Wrona
    COO

    Leadership positions in product and project management, early-stage fund-raising, preclinical and clinical strategy.

  • Bernd Seizinger
    CEO

    Executive leadership positions as Vice President, Oncology Drug Discovery and Molecular Genetics at Bristol-Myers Squibb; President and CEO GPC Biotech; Executive Chairman at Aprea and Opsona; former Senior Faculty at Harvard Medical School, Massachusetts General Hospital and Princeton University
    Led two successful initial public offerings (IPOs) each of them having raised more than $100 million.

  • Hemanshu Shah
    Business Development Officer

    Pharmaceutical/biotechnology executive with experience in multiple therapeutic areas including substantial experience in oncology therapeutics, such as at Bristol-Myers Squibb, in- and out-licensing and corporate partnerships.

  • Marcel Rozencweig
    Chief Medical Officer

    former worldwide head of clinical oncology at Bristol-Myers Squibb. One of the most successful oncology drug developers of all times: More than a dozen drug approvals.

Advisors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free